Use of recombinant C1 inhibitor in patients with resistant or frequent attacks of hereditary or acquired angioedema

European Journal of Dermatology

Volumn 24, Issue 1, 2014, Pages 28-34

  Manson, Ania L ^a   Dempster, John ^a   Grigoriadou, Sofia ^a   Buckland, Matthew S ^a   Longhurst, Hilary J ^a  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

Acquired angioedema; Hereditary angioedema; Recombinant C1 inhibitor

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; OXANDROLONE; STANOZOLOL; RECOMBINANT PROTEIN; SERPING1 PROTEIN, HUMAN;

ABDOMINAL PAIN; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SELF ADMINISTRATION; EMERGENCY TREATMENT; FEMALE; HUMAN; LEG SWELLING; MALE; MIDDLE AGED; SINGLE DRUG DOSE; TREATMENT RESPONSE; UNITED KINGDOM; YOUNG ADULT; ANGIOEDEMA; ANGIOEDEMAS, HEREDITARY; CLINICAL TRIAL; DRUG RESISTANCE; RECURRENT DISEASE;

ADULT; ANGIOEDEMA; ANGIOEDEMAS, HEREDITARY; COMPLEMENT C1 INACTIVATOR PROTEINS; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RECURRENCE; YOUNG ADULT;

EID: 84897506166     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2013.2252     Document Type: Article

References (35)

1. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 2008; 359: 1027-36.
2. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012; 130: 692-7.
3. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119: 267-74.
4. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med 2001; 161: 2417-29.
5. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71: 206-15.
6. Longhurst H, Cicardi M. Hereditary angio-oedema. Lancet 2012; 379: 474-81.
7. Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003; 3: 311-7.
8. Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010; 6: 22.
9. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykininreceptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-41.
10. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010; 363: 523-31.
11. Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtulowicz K, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124: 801-8.
12. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363: 513-22.
13. Lock RJ, Gompels MM. C1-inhibitor deficiencies (hereditary angioedema): where are we with therapies? Curr Allergy Asthma Rep 2007; 7: 264-9.
14. Longhurst H. Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia. Curr Opin Investig Drugs 2008; 9: 310-23.
15. van Veen HA, Koiter J, Vogelezang CJ, et al. Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits. J Biotechnol 2012; 162: 319-26.
16. RuconestTM: Immunological assessments non-promotional educational materials for prescribers. 2010.
17. Hack CE, Mannesse M, Baboeram A, Oortwijn B, Relan A. Immunogenicity assessment of recombinant human c1-inhibitor: an integrated analysis of clinical studies. BioDrugs 2012; 26: 303-13.
18. Biovitrum SO. Ruconest 2100 U power for solution for injection. Summary of Product Characteristics (SPC). 2011.
19. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124: 801-8.
20. Hack CE, Relan A, van Amersfoort ES, Cicardi M. Target levels of functional C1-inhibitor in hereditary angioedema. Allergy 2012; 67: 123-30.
21. Zuraw B, Cicardi M, Levy RJ et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010; 126: 821-7 e14.
22. Moldovan D, Reshef A, Fabiani J, et al. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. Clin Exp Allergy 2012; 42: 929-35.
23. Riedl MA, Levy RJ, Suez D, et al. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Ann Allergy Asthma Immunol 2013; 110: 295-9.
24. Kusuma A, Relan A, Knulst AC et al. Clinical impact of peripheral attacks in hereditary angioedema patients. Am J Med 2012; 125: 937 e17-24.
25. Cicardi M, Zingale LC, Pappalardo E, Folcioni A, Agostoni A. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore) 2003; 82: 274-81.
26. Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006; 117: 904-8.
27. Cicardi M, Johnston DT. Hereditary and acquired complement component 1 esterase inhibitor deficiency: a review for the hematologist. Acta Haematol 2012; 127: 208-20.
28. Manson AL, Price A, Dempster J, et al. In pursuit of excellence: An Integrated Care Pathway for C1 Inhibitor Deficiency. Clin Exp Immunol 2013; 173: 1-7.
29. Bright P, Dempster J, Longhurst H. Successful treatment of acquired C1 inhibitor deficiency with icatibant. Clin Exp Dermatol 2010; 35: 553-4.
30. Liccardi G, Passalacqua G. Sensitization to rabbit allergens in Italy-a multicentre study in atopic subjects without occupational exposure. Int Arch Allergy Immunol 2006; 141: 295-9.
31. Hauert J, Patston PA, Schapira M. C1 inhibitor cross-linking by tissue transglutaminase. J Biol Chem 2000; 275: 14558-62.
32. Patston PA, Gettins P, Beechem J, Schapira M. Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. Biochemistry 1991; 30: 8876-82.
33. Cicardi M, Zanichelli A. Acquired angioedema. Allergy Asthma Clin Immunol 2010; 6: 14.
34. Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 2007; 47: 1028-32.
35. Farrell C, Hayes S, Relan A, van Amersfoort ES, Pijpstra R, Hack CE. Population pharmacokinetics of recombinant human C1-inhibitor in patients with hereditary angioedema. Br J Clin Pharmacol 2013.